Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AMSNASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.76-1.4%$2.77$2.51▼$4.60$17.72M0.6643,765 shs6,363 shsSLNSilence Therapeutics$3.83+3.5%$3.39$1.97▼$24.38$114.63M1.2298,114 shs162,205 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services0.00%+0.36%+3.32%+4.48%+4.48%SLNSilence Therapeutics0.00%-5.85%+43.97%-24.80%-82.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMSAmerican Shared Hospital Services1.4906 of 5 stars0.03.00.00.02.21.71.9SLNSilence Therapeutics2.6579 of 5 stars4.41.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMSAmerican Shared Hospital Services 0.00N/AN/AN/ASLNSilence Therapeutics 2.71Moderate Buy$33.83783.38% UpsideCurrent Analyst Ratings BreakdownLatest AMS, TSTL, SLN, and CSRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.003/7/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/5/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.003/4/2025SLNSilence TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.003/4/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$6.00 ➝ $4.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMSAmerican Shared Hospital Services$21.33M0.83$0.93 per share2.97$4.17 per share0.66SLNSilence Therapeutics$43.26M2.65N/AN/A$0.71 per share5.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMSAmerican Shared Hospital Services$610K$0.604.609.20N/A15.74%4.01%2.11%5/13/2025 (Estimated)SLNSilence Therapeutics-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%5/15/2025 (Estimated)Latest AMS, TSTL, SLN, and CSRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million5/13/2025Q1 2025AMSAmerican Shared Hospital Services$0.04N/AN/AN/A$7.70 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMSAmerican Shared Hospital Services0.341.461.46SLNSilence TherapeuticsN/A9.319.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMSAmerican Shared Hospital Services23.16%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipAMSAmerican Shared Hospital Services23.00%SLNSilence Therapeutics2.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMSAmerican Shared Hospital Services106.42 million4.94 millionNot OptionableSLNSilence Therapeutics10029.93 millionN/ANot OptionableAMS, TSTL, SLN, and CSRT HeadlinesRecent News About These CompaniesMorgan Stanley Lowers Silence Therapeutics (NASDAQ:SLN) Price Target to $25.00May 12 at 1:44 AM | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan CapitalMay 11 at 8:43 AM | marketbeat.comSilence Therapeutics (SLN) Projected to Post Quarterly Earnings on ThursdayMay 10 at 1:53 AM | marketbeat.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comCantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)May 7, 2025 | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comBoothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)April 30, 2025 | marketbeat.comMarshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)April 28, 2025 | marketbeat.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by BrokeragesApril 20, 2025 | marketbeat.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comSilence Therapeutics (SLN) Upgraded to Buy: Here's What You Should KnowMarch 4, 2025 | zacks.comSilence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2025 | uk.finance.yahoo.comSilence Therapeutics plc (SLN) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comSilence Quiets Phase III Pace for Lipoprotein Drug, Seeks PartnerFebruary 28, 2025 | biospace.comSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | businesswire.comGoldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell RecommendationFebruary 11, 2025 | msn.comSilence Therapeutics hit with new Sell at Goldman Sachs on resource constraintsFebruary 11, 2025 | seekingalpha.comGoldman starts Silence Therapeutics at Sell on ‘undifferentiated’ dataFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum3 Tech Leaders Announce Buybacks Totaling $85 BillionBy Leo Miller | May 5, 2025View 3 Tech Leaders Announce Buybacks Totaling $85 BillionRocket Lab's Growth Potential Gains Altitude on Defense NewsBy Ryan Hasson | April 17, 2025View Rocket Lab's Growth Potential Gains Altitude on Defense NewsWhy Investors Should Be Careful About AMC's Bitcoin DreamsBy Gabriel Osorio-Mazilli | May 8, 2025View Why Investors Should Be Careful About AMC's Bitcoin DreamsAMS, TSTL, SLN, and CSRT Company DescriptionsAmerican Shared Hospital Services NYSEAMERICAN:AMS$2.76 -0.04 (-1.43%) Closing price 04:10 PM EasternExtended Trading$2.81 +0.05 (+1.81%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.Silence Therapeutics NASDAQ:SLN$3.83 +0.13 (+3.51%) Closing price 04:00 PM EasternExtended Trading$3.90 +0.07 (+1.85%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
